STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] ANI Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

ANI Pharmaceuticals, Inc. (ANIP) Form 144 reports a proposed sale of 6,865 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,223.68. The filing lists the approximate number of shares outstanding as 21,688,772 and an approximate sale date of 08/18/2025 on NASDAQ.

The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they do not possess undisclosed material adverse information.

Positive
  • Notice filed under Rule 144 with broker identified (Morgan Stanley Smith Barney LLC)
  • Full acquisition details provided: date, nature (restricted stock), and source (issuer)
  • No sales in the past three months reported, clarifying recent trading activity
Negative
  • None.

Insights

TL;DR: Routine Rule 144 notice for a proposed sale of restricted shares; disclosure aligns with regulatory requirements.

The filing documents a proposed sale under Rule 144 using a registered broker, naming Morgan Stanley Smith Barney LLC, and provides required details: class, quantity, acquisition date, nature of acquisition, aggregate market value, and intended sale date. The inclusion of a statement that there have been no sales in the past three months and the standard attestation about material non-public information are consistent with standard compliance practices for insiders or restricted holders preparing to sell.

TL;DR: Small, disclosed sale of restricted shares; unlikely to be materially impactful to ANIP’s capitalization.

The notice specifies 6,865 shares valued at $616,223.68 and lists 21,688,772 shares outstanding, with the shares acquired from the issuer as restricted stock on 05/23/2024. The filing contains no indication of prior recent sales and does not report any unusual transaction structures. From an investor-information standpoint, this is a transparent disclosure of a planned sale rather than a material corporate event.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ANIP Form 144 report?

The filing reports a proposed sale of 6,865 common shares with an aggregate market value of $616,223.68, to be sold through Morgan Stanley Smith Barney LLC on or about 08/18/2025.

When and how were the shares acquired for this ANIP Form 144?

The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date.

Does the filing indicate recent sales of ANIP shares by the filer?

The filing states Nothing to Report for securities sold during the past three months, indicating no reported recent sales.

Which exchange and broker are involved in the proposed ANIP sale?

The proposed sale is listed for NASDAQ and the broker named is Morgan Stanley Smith Barney LLC.

What statement does the filer make about material non-public information?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Ani Pharmaceutic

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data

1.76B
19.14M
10.42%
97.8%
9.42%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BAUDETTE